CN102227223B - Mineral absorption improver, and method for improving absorption of minerals - Google Patents
Mineral absorption improver, and method for improving absorption of minerals Download PDFInfo
- Publication number
- CN102227223B CN102227223B CN2009801476120A CN200980147612A CN102227223B CN 102227223 B CN102227223 B CN 102227223B CN 2009801476120 A CN2009801476120 A CN 2009801476120A CN 200980147612 A CN200980147612 A CN 200980147612A CN 102227223 B CN102227223 B CN 102227223B
- Authority
- CN
- China
- Prior art keywords
- mineral absorption
- improving agent
- mineral
- oligosaccharide
- dairy product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229910052500 inorganic mineral Inorganic materials 0.000 title claims abstract description 119
- 239000011707 mineral Substances 0.000 title claims abstract description 119
- 238000010521 absorption reaction Methods 0.000 title claims abstract description 110
- 238000000034 method Methods 0.000 title description 11
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 56
- 239000011701 zinc Substances 0.000 claims abstract description 56
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 56
- 229920001542 oligosaccharide Polymers 0.000 claims abstract description 50
- 150000002482 oligosaccharides Chemical class 0.000 claims abstract description 49
- 235000013305 food Nutrition 0.000 claims abstract description 30
- 239000000203 mixture Substances 0.000 claims abstract description 28
- 239000003795 chemical substances by application Substances 0.000 claims description 68
- 235000021001 fermented dairy product Nutrition 0.000 claims description 52
- 235000013336 milk Nutrition 0.000 claims description 40
- 239000008267 milk Substances 0.000 claims description 40
- 210000004080 milk Anatomy 0.000 claims description 40
- 229930182830 galactose Natural products 0.000 claims description 29
- 235000013351 cheese Nutrition 0.000 claims description 26
- 239000007787 solid Substances 0.000 claims description 24
- 241000186660 Lactobacillus Species 0.000 claims description 21
- 229940039696 lactobacillus Drugs 0.000 claims description 21
- 239000000470 constituent Substances 0.000 claims description 20
- 230000005070 ripening Effects 0.000 claims description 17
- 239000004615 ingredient Substances 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 241000194017 Streptococcus Species 0.000 claims description 8
- 230000027119 gastric acid secretion Effects 0.000 claims description 7
- 238000000855 fermentation Methods 0.000 claims description 6
- 230000004151 fermentation Effects 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 abstract description 4
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 2
- 230000002378 acidificating effect Effects 0.000 abstract 2
- 235000014048 cultured milk product Nutrition 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 abstract 1
- 150000003271 galactooligosaccharides Chemical class 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 235000010755 mineral Nutrition 0.000 description 95
- 230000009102 absorption Effects 0.000 description 86
- 230000000694 effects Effects 0.000 description 16
- 102000011632 Caseins Human genes 0.000 description 15
- 108010076119 Caseins Proteins 0.000 description 15
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 14
- 239000005018 casein Substances 0.000 description 12
- 235000021240 caseins Nutrition 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 241000700159 Rattus Species 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- 229940088594 vitamin Drugs 0.000 description 10
- 229930003231 vitamin Natural products 0.000 description 10
- 235000013343 vitamin Nutrition 0.000 description 10
- 239000011782 vitamin Substances 0.000 description 10
- 238000002835 absorbance Methods 0.000 description 9
- 150000001720 carbohydrates Chemical class 0.000 description 9
- -1 oligofructose Chemical class 0.000 description 9
- 102000007544 Whey Proteins Human genes 0.000 description 8
- 108010046377 Whey Proteins Proteins 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 7
- 239000011575 calcium Substances 0.000 description 7
- 229910052791 calcium Inorganic materials 0.000 description 7
- 210000004211 gastric acid Anatomy 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 239000008101 lactose Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 229940126409 proton pump inhibitor Drugs 0.000 description 7
- 229920002472 Starch Polymers 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 5
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 5
- 239000005862 Whey Substances 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 229910052802 copper Inorganic materials 0.000 description 5
- 239000010949 copper Substances 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 235000020183 skimmed milk Nutrition 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 229920001202 Inulin Polymers 0.000 description 4
- 102000004407 Lactalbumin Human genes 0.000 description 4
- 108090000942 Lactalbumin Proteins 0.000 description 4
- 241000194036 Lactococcus Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 206010048259 Zinc deficiency Diseases 0.000 description 4
- 102000005936 beta-Galactosidase Human genes 0.000 description 4
- 108010005774 beta-Galactosidase Proteins 0.000 description 4
- 235000014121 butter Nutrition 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 239000003925 fat Substances 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- 235000021050 feed intake Nutrition 0.000 description 4
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 4
- 229940029339 inulin Drugs 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 108090000746 Chymosin Proteins 0.000 description 3
- 241000194032 Enterococcus faecalis Species 0.000 description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- 229940080701 chymosin Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000008504 concentrate Nutrition 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940032049 enterococcus faecalis Drugs 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 150000002338 glycosides Chemical class 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- GNOLWGAJQVLBSM-UHFFFAOYSA-N n,n,5,7-tetramethyl-1,2,3,4-tetrahydronaphthalen-1-amine Chemical compound C1=C(C)C=C2C(N(C)C)CCCC2=C1C GNOLWGAJQVLBSM-UHFFFAOYSA-N 0.000 description 3
- 229960003512 nicotinic acid Drugs 0.000 description 3
- 235000001968 nicotinic acid Nutrition 0.000 description 3
- 239000011664 nicotinic acid Substances 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 235000021119 whey protein Nutrition 0.000 description 3
- 235000013618 yogurt Nutrition 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- PVXPPJIGRGXGCY-DJHAAKORSA-N 6-O-alpha-D-glucopyranosyl-alpha-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@](O)(CO)O1 PVXPPJIGRGXGCY-DJHAAKORSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000193752 Bacillus circulans Species 0.000 description 2
- 241000186012 Bifidobacterium breve Species 0.000 description 2
- 241001608472 Bifidobacterium longum Species 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 206010048768 Dermatosis Diseases 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010013911 Dysgeusia Diseases 0.000 description 2
- 208000005922 Glossalgia Diseases 0.000 description 2
- 208000002705 Glucose Intolerance Diseases 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 240000001046 Lactobacillus acidophilus Species 0.000 description 2
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 2
- 240000001929 Lactobacillus brevis Species 0.000 description 2
- 235000013957 Lactobacillus brevis Nutrition 0.000 description 2
- 244000199866 Lactobacillus casei Species 0.000 description 2
- 235000013958 Lactobacillus casei Nutrition 0.000 description 2
- 241001147746 Lactobacillus delbrueckii subsp. lactis Species 0.000 description 2
- 241000186606 Lactobacillus gasseri Species 0.000 description 2
- 240000002605 Lactobacillus helveticus Species 0.000 description 2
- 235000013967 Lactobacillus helveticus Nutrition 0.000 description 2
- 241000394636 Lactobacillus mucosae Species 0.000 description 2
- 241000186871 Lactobacillus murinus Species 0.000 description 2
- 240000006024 Lactobacillus plantarum Species 0.000 description 2
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 2
- 241000186604 Lactobacillus reuteri Species 0.000 description 2
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 2
- 241000194034 Lactococcus lactis subsp. cremoris Species 0.000 description 2
- 241000192132 Leuconostoc Species 0.000 description 2
- 241000222051 Papiliotrema laurentii Species 0.000 description 2
- 241000186429 Propionibacterium Species 0.000 description 2
- 201000001880 Sexual dysfunction Diseases 0.000 description 2
- 235000014962 Streptococcus cremoris Nutrition 0.000 description 2
- 244000057717 Streptococcus lactis Species 0.000 description 2
- 235000014897 Streptococcus lactis Nutrition 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- FYGDTMLNYKFZSV-ANKSBSNASA-N alpha-D-Gal-(1->4)-beta-D-Gal-(1->4)-D-Glc Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-ANKSBSNASA-N 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 229940009291 bifidobacterium longum Drugs 0.000 description 2
- 235000015155 buttermilk Nutrition 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000004640 cellular pathway Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000002079 cooperative effect Effects 0.000 description 2
- 235000015140 cultured milk Nutrition 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 235000019564 dysgeusia Nutrition 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000013350 formula milk Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 206010018388 glossodynia Diseases 0.000 description 2
- 230000007813 immunodeficiency Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000009940 knitting Methods 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 229940017800 lactobacillus casei Drugs 0.000 description 2
- 229940054346 lactobacillus helveticus Drugs 0.000 description 2
- 229940072205 lactobacillus plantarum Drugs 0.000 description 2
- 229940001882 lactobacillus reuteri Drugs 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 235000021142 long-term diet Nutrition 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 235000003715 nutritional status Nutrition 0.000 description 2
- 238000009928 pasteurization Methods 0.000 description 2
- 201000009104 prediabetes syndrome Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000000612 proton pump inhibitor Substances 0.000 description 2
- 235000020201 recombined milk Nutrition 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000014860 sensory perception of taste Effects 0.000 description 2
- 231100000872 sexual dysfunction Toxicity 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000001228 trophic effect Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 235000008939 whole milk Nutrition 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- ZFTFOHBYVDOAMH-XNOIKFDKSA-N (2r,3s,4s,5r)-5-[[(2r,3s,4s,5r)-5-[[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-2-(hydroxymethyl)oxolan-2-yl]oxymethyl]-2-(hydroxymethyl)oxolane-2,3,4-triol Chemical class O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(OC[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 ZFTFOHBYVDOAMH-XNOIKFDKSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 102100034279 Calcium-binding mitochondrial carrier protein Aralar2 Human genes 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- UNPLRYRWJLTVAE-UHFFFAOYSA-N Cloperastine hydrochloride Chemical compound Cl.C1=CC(Cl)=CC=C1C(C=1C=CC=CC=1)OCCN1CCCCC1 UNPLRYRWJLTVAE-UHFFFAOYSA-N 0.000 description 1
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical group CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000194031 Enterococcus faecium Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229920002670 Fructan Polymers 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 229940122957 Histamine H2 receptor antagonist Drugs 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 description 1
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 1
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 1
- 241000186784 Lactobacillus oris Species 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 102000008192 Lactoglobulins Human genes 0.000 description 1
- 108010060630 Lactoglobulins Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 108010070551 Meat Proteins Proteins 0.000 description 1
- 206010061291 Mineral deficiency Diseases 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 241000192001 Pediococcus Species 0.000 description 1
- 108010001441 Phosphopeptides Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 241001627955 Tetraodon lineatus Species 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 206010060926 abdominal symptom Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-HEJLOQJISA-N beta-D-galactopyranosyl-(1->4)-D-galactopyranose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-HEJLOQJISA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 235000020246 buffalo milk Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 229940071162 caseinate Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 108010084210 citrin Proteins 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 235000020965 cold beverage Nutrition 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 235000012495 crackers Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000010855 food raising agent Nutrition 0.000 description 1
- 235000013611 frozen food Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000020251 goat milk Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 239000003485 histamine H2 receptor antagonist Substances 0.000 description 1
- 235000020252 horse milk Nutrition 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 229940068140 lactobacillus bifidus Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 229940063517 omeprazole sodium Drugs 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000020254 sheep milk Nutrition 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- KNVABRFVZVESIL-UHFFFAOYSA-N sodium;6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1h-benzimidazole Chemical compound [Na+].N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C KNVABRFVZVESIL-UHFFFAOYSA-N 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046001 vitamin b complex Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 235000021249 α-casein Nutrition 0.000 description 1
- 235000021247 β-casein Nutrition 0.000 description 1
- 235000021246 κ-casein Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C19/00—Cheese; Cheese preparations; Making thereof
- A23C19/06—Treating cheese curd after whey separation; Products obtained thereby
- A23C19/068—Particular types of cheese
- A23C19/076—Soft unripened cheese, e.g. cottage or cream cheese
- A23C19/0765—Addition to the curd of additives other than acidifying agents, dairy products, proteins except gelatine, fats, enzymes, microorganisms, NaCl, CaCl2 or KCl; Foamed fresh cheese products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
- A23C9/1307—Milk products or derivatives; Fruit or vegetable juices; Sugars, sugar alcohols, sweeteners; Oligosaccharides; Organic acids or salts thereof or acidifying agents; Flavours, dyes or pigments; Inert or aerosol gases; Carbonation methods
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
Provided is a mineral absorption improver which has excellent safety and excellent taste, can be ingested for a long period, and can improve the absorption of minerals. The mineral absorption improver comprises an oligosaccharide and a fermented milk product as active ingredients. The mineral absorption improver can improve the absorption of minerals, particularly zinc, by a synergistic effect of the oligosaccharide and the fermented milk product, even though the mineral absorption improver is a composition having a lower oligosaccharide content than those of the conventional mineral absorption improvers. When the mineral absorption improver is prepared using galactooligosaccharide which is a compound hardly decomposed under acidic conditions, as the oligosaccharide, the mineral absorption improver can be added to compositions such as acidic foods and pharmaceutical preparations.
Description
Technical field
The present invention relates to contain oligosaccharide and fermented dairy product as mineral absorption improving agent and the mineral absorption improvement method of effective ingredient.
Background technology
Now, in Japan, the people that the intake of mineral does not reach average requirement is very many.By inference, there is 30～40% Japanese particularly not reach average requirement (non-patent literature 1) for the intake of zinc.And, in recent years, pointed out the potential zinc deficiency patient of Japan very many, the improvement of the nutritional status of zinc begin to come into one's own (non-patent literature 2).As zinc deficiency, known hypoevolutism and unusual, sexual dysfunction, anemia, immunodeficiency, dermatosis, diarrhoea, wound healing are slow, the generation of decubital ulcer and cure slow, inappetence and go down, (non-patent literatures 2) such as dysgeusias, glossodynia, impaired glucose tolerance.It is believed that, for prevention and the improvement of zinc deficiency, importantly increase the absorbance of zinc intake and increase zinc.On the other hand, the picked-up of known a large amount of zinc hinders the usability (non-patent literature 3) of the trace element such as copper.Therefore think, in order to improve the nutritional status of zinc, more preferably increase the absorbance of zinc.
Known, the indigestibility saccharides such as oligofructose, inulin, oligomeric galactose make the absorbance of mineral increase (patent documentation 1～6, non-patent literature 4).For example, the supply of the mineral of known oligomeric galactose after to stomach resecting operation is useful (patent documentation 3).
Existence absorbs with zinc and improves the report that material increases the absorbance of zinc, but the negligible amounts of such report.For example, it is reported, increase as the mixture (non-patent literature 6) of oligofructose (non-patent literature 5), oligofructose and the inulin of indigestibility saccharide, the absorbance that inulin (non-patent literature 7) makes respectively zinc.But, the dosage that mineral absorption when these zinc absorb the dosage of improving material than the absorbance that improves calcium etc. improves material is large, and these zinc absorptions improve the content of material in the feedstuff of the picked-up media such as food compositions and are respectively 10 quality %, 10 quality %, 7.5 quality %.And, reported the absorption to zinc when being lower than this dosage do not exert an influence (non-patent literature 8).And, about oligomeric galactose, do not make the report of the absorption increase of zinc.For indigestibility saccharides such as oligosaccharide, the increase of concomitant dosing amount, the incidence rate of the gastrointestinal symptoms such as diarrhoea increases (non-patent literature 9,10).Therefore think it is desirable to, promote the effect of the mineral absorptions such as zinc with less dosage performance.
In addition, have been reported, oligofructose can be hydrolyzed (non-patent literature 11) under highly acid, and oligomeric galactose has under acid condition and heating condition under be difficult to produce the character (non-patent literature 12) of the decay due to decomposing etc.
It is reported, as the factor that affects mineral absorption, can enumerate (non-patent literature 13 and non-patent literatures 14) such as trophic factors such as the intake of its mineral itself and dissolubility and other mineral, vitamin, protein.
The prior art document
Patent documentation
Patent documentation 1: Japanese kokai publication hei 4-134031 communique
Patent documentation 2: Japanese kokai publication hei 7-069902 communique
Patent documentation 3:WO98/015196 communique
Patent documentation 4: No. 3933702 communique of Japan Patent
Patent documentation 5: No. 3279695 communique of Japan Patent
Patent documentation 6: No. 3179090 communique of Japan Patent
Non-patent literature
Non-patent literature 1: be Chuan Jia then, the 1st Knitting ミ ネ ラ Le base Foundation know Knowledge, the 2nd chapter ミ ネ ラ Le necessary amount と feeding taken amount-national health Sakae Raising Tone Check To ょ Ru investigate-, the up-to-date ying of in ミ ネ ラ Le science と with skill Intraoperative (investigation of the rudimentary knowledge of the 1st mineral, the necessary amount of the 2nd chapter mineral and intake-national health and nutritional survey-, in science and the more recent application technology of mineral), CMC publish, the chief editor: a Chuan Jia then, pp.12-20 (2008)
Non-patent literature 2: storehouse Ze Longping, of a specified duration hole Zhou Zhilang, the 2nd Knitting feeding taken amount To Seki The Ru Ask Questions, the 2nd chapter Pro bed Now Games To ぉ け Ru ミ ネ ラ Le (Ami lead) feeding get Ask Questions point, the up-to-date ying of in ミ ネ ラ Le science と with skill Intraoperative (problem of the problem of the 2nd relevant intake, the clinical mineral of the 2nd chapter (zinc) picked-up, in science and the more recent application technology of mineral matter), CMC publication, edit: be Chuan Jia, pp.48-61 (2008)
Non-patent literature 3:O ' Dell BL., Mineral interactions relevant tonutrient requirements.J Nutr.119 (12 Suppl), pp.1832-1838 (1989)
Non-patent literature 4:Zafar TA, Weaver CM, Zhao Y, Martin BR, Wastney ME., Nondigestible oligosaccharides increase calcium absorption and suppress bone resorption in ovariectomized rats., J Nutr., 134 (2), pp.399-402 (2004)
Non-patent literature 5:Delzenne N, Aertssens J, Verplaetse H, Roccaro M, Roberfroid M., Effect of fermentable fructo-oligosaccharides onmineral, nitrogen and energy digestive balance in the rat., Life Sci., 57 (17), pp.1579-1587 (1995)
Non-patent literature 6:Raschka L, Daniel H., Diet composition andage determine the effects of inulin-type fructans on intestinal calcium absorption in rat., Eur J Nutr., 44 (6), pp.360-364 (2005)
Non-patent literature 7:Coudray C, Feillet-Coudray C, Gueux E, Mazur A, Rayssiguier Y., Dietary inulin intake and age can affect intestinal absorption of zinc and copper in rats., J Nutr., 136 (1), pp.117-122 (2006)
Non-patent literature 8:Wolf BW, Firkins JL, Zhang X., Varyingdietary concentrations of fructooligosaccharides affect apparent absorption and balance of minerals in growing rats., Nutr Res., 18 (10), pp.1791-1806 (1998)
Non-patent literature 9:Hata Y, Nakajima K., Studies onrelationship between intake of fructooligosaccharides and abdominal symptoms-Estimation of the maximum non-effective dose and 50 % laxative effective dose., Geriatric Medicine., 23 (5), pp.817-828 (1985)
Non-patent literature 10:Marteau P, Flourie B.Tolerance tolow-digestible carbohydrates:symptomatology and methods.Br J Nutr.85 (Suppl 1) pp.S17-21 (2001)
Non-patent literature 11:Atsuko NAKAMURA, Off Le Network ト ォ リ go sugar The changes (used the sweet and sour pork of oligofructose or the dish that boils in sugared variation), university of Tokyo housekeeping institute summary, 43, pp.49-53 (2003) with In sugar in the ぃ jealous woman globefish ゃ Stewed Dish
Non-patent literature 12: the pool enters refined people, ガ ラ Network ト ォ リ ゴ Tang Machine can と food へ ying (function of oligomeric galactose and Applications in food), FOOD STYLE 21,2, pp.76-78 (1998)
Non-patent literature 13:Lonnerdal B, Dietary factors influencing zinc absorption, J Nutr, 130, pp.1378S-1383S (2000)
Non-patent literature 14:Sandstrom B, Micronutrient interactions:effects on absorption and bioavailability, Br JNutr, 85, pp.181S-185S (2001)
Summary of the invention
Invent problem to be solved
The object of the present invention is to provide mineral absorption improving agent and mineral absorption improvement method, although described mineral absorption improving agent its content in the solid constituent total amount of this picked-up medium when using with the form of the picked-up media such as food compositions, pharmaceutical composition is lower than in the past, also can bring into play the mineral absorption facilitation effect.
The means of dealing with problems and adopting
The inventor finds, by containing oligosaccharide and fermented dairy product as the mineral absorption improving agent of effective ingredient, and the above-mentioned purpose of attainable cost invention, thus finished the present invention.
That is, the invention provides following [1]～[15].
[1] a kind of mineral absorption improving agent, it contains oligosaccharide and fermented dairy product as effective ingredient.
[2] such as above-mentioned [1] described mineral absorption improving agent, wherein, described oligosaccharide is to contain galactose as the oligosaccharide that consists of sugar.
[3] such as above-mentioned [2] described mineral absorption improving agent, wherein, containing described galactose is oligomeric galactose as the oligosaccharide that consists of sugar.
[4] such as each described mineral absorption improving agent of above-mentioned [1]～[3], wherein, described fermented dairy product is to utilize the lactobacillus that belongs to Lactobacillus and the lactobacillus that belongs to Streptococcus that the milk fermentation is obtained.
[5] such as each described mineral absorption improving agent of above-mentioned [1]～[4], wherein, described fermented dairy product is non-ripening cheese.
[6] such as each described mineral absorption improving agent of above-mentioned [1]～[5], be zinc as the mineral that absorbs the object that improves.
[7] such as each described mineral absorption improving agent of above-mentioned [1]～[6], wherein, this mineral absorption improving agent further contains zinc.
[8] such as each described mineral absorption improving agent of above-mentioned [1]～[7], it is food compositions.
[9] such as each described mineral absorption improving agent of above-mentioned [1]～[7], it is pharmaceutical composition.
[10] such as each described mineral absorption improving agent of above-mentioned [1]～[9], wherein, the content of described oligosaccharide in the solid constituent total amount of described mineral absorption improving agent is 1.0～7.0 quality %, and the mass ratio of described fermented dairy product/described oligosaccharide (solid constituent scaled value) is 1.0～49.0.
[11] such as above-mentioned [10] described mineral absorption improving agent, wherein, the mass ratio of described fermented dairy product/above-mentioned oligosaccharide (solid constituent scaled value) is 1.0～30.0.
[12] such as above-mentioned [11] described mineral absorption improving agent, wherein, the mass ratio of described fermented dairy product/described oligosaccharide (solid constituent scaled value) is 1.0～9.0.
[13] such as above-mentioned [12] described mineral absorption improving agent, wherein, the mass ratio of described fermented dairy product/described oligosaccharide (solid constituent scaled value) is 3.0～8.0.
[14] such as each described mineral absorption improving agent of above-mentioned [1]～[13], it is used for improving gastric acid secretion minimizing person's mineral absorption.
[15] a kind of mineral absorption improvement method wherein, makes the people absorb simultaneously oligosaccharide and fermented dairy product.
The invention effect
Mineral absorption improving agent of the present invention can be brought into play the effect of the absorption that promotes mineral, particularly zinc by the cooperative effect of oligosaccharide and fermented dairy product.
More particularly, mineral absorption improving agent of the present invention is when using with the form of the picked-up media such as food compositions, pharmaceutical composition, be lower than the content of prior art even determine its content in the solid constituent total amount of this picked-up medium, for example mineral absorption improving agent of the present invention is below the 7.0 quality %, also can bring into play the mineral absorption facilitation effect.
And mineral absorption improving agent of the present invention, can absorb so there is not the problem of side effect for a long time owing to only contain by the long-term diet experience of the mankind and confirm to have the oligosaccharide of excellent safety and the sense of taste and fermented dairy product as neccessary composition.
And then, mineral absorption improving agent of the present invention, can use with the food compositions of acidity or the form of pharmaceutical composition during as oligosaccharide at the oligosaccharide of the character of the decay due to use has the decomposition that is difficult for being created under the acid condition etc., for example oligomeric galactose.
The accompanying drawing simple declaration
Fig. 1 is that expression is combined with the feedstuff of oligomeric galactose and fermented dairy product to the curve chart of the impact of apparent zinc absorbance (meansigma methods ± standard deviations of the one group 8) generation of rat.
The specific embodiment
Prepare mineral absorption improving agent of the present invention with oligosaccharide as the part of mineral absorption improving agent.
In the present invention, oligosaccharide is also referred to as oligosaccharide, refers to that 2～20 sugar carry out the chemical compound that glycoside link forms.As oligosaccharide, can enumerate such as oligomeric lactose, oligomeric isomaltose, oligofructose, oligomeric galactose, oligomeric xylose, soybean oligo saccharide, ニ ゲ ロ ォ リ go sugar (Nigerooligosaccharide), oligomeric dragon gallbladder sugar, lactose, sucrose, maltose, trehalose, palatinose (palatinose) etc., but be not limited to these examples.When mineral absorption improving agent of the present invention was acid, the preferred use had the oligosaccharide that is difficult for producing the character of decomposing the decay due to waiting.
In the present invention, also can use and contain galactose as the oligosaccharide that consists of sugar.Consist of the oligosaccharide that comprises galactose in the sugar and refer to that 2～20 sugar carry out chemical compound that glycoside link forms, comprise one or more galactose in the sugar that consists of chemical compound.As its example, can enumerate raffinose family oligosaccharide (soybean oligo saccharide), oligomeric galactose etc.In the present invention, oligomeric galactose refers to contain galactose as the oligosaccharide of main formation sugar.Take lactose (Gal (β 1-4) Glc) as basic structure and have bonding thereon have the structure of 1～several galactose residues oligosaccharide, have disaccharides (transfer disaccharides), Gal-(Gal) n-Glc (n=1～18), Gal-(Gal) n-Gal (n=1～18) of galactose and glucose to be also contained in the example of oligomeric galactose with mode bondings such as β-1,3 bondings.As an example of the industrially preparing process of oligomeric galactose, can enumerate the beta galactosidase (being mainly derived from the microorganisms such as Cryptococcus laurentii (Cryptococcus laurentii), Bacillus circulans (Bacillus circulans) etc.) that makes the galactose transfer ability high act on the method that lactose makes (pool enter refined people, ガ ラ Network ト ォ リ ゴ Tang Machine can と food へ ying with, FOOD STYLE 21,2, pp.76-78 (1998)).And, in the specification benchmark of specific food for health care (specification reference model) system, oligomeric galactose is defined as by beta galactosidase (derives from β-D-galactoside galactohydrolase (β-D-galactoside galactohydrolase), E.C.3.2.1.23, the Cryptococcus yeast) effect is glycogenetic by breast, glycoside link has one or more galactose on the galactose residue of lactose, (the food peace on July 1st, 2005 is sent out the food safety minister of medicine food office of MHLW notice No. 0701007 to oligosaccharide take 4 '-galactosyl lactose (Gal (β 1-4) Gal (β 1-4) Glc) as main constituent, " setting of the specification benchmark of following about the establishment of specific food for health care (specification reference model) system etc. ").Oligomeric galactose is contained in the breast milk, has the effect of the lactobacillus bifidus that increases enteral, and is sugared known as what be difficult to digest and assimilate.
Prepare mineral absorption improving agent of the present invention with fermented dairy product as the part of mineral absorption improving agent.
The fermented dairy product that uses among the present invention refers to use the leaven such as lactobacillus to make the liquid milk fermentation and whole milk product of obtaining, and described liquid milk is modulated the one kind or two or more combination in the domestic animals such as milk, buffalo milk, Goat Milk, sheep milk, horse milk milk and/or these partially skimmed milk, defatted milk, recombined milk, reduction defatted milk, reduction partially skimmed milk, milk surum, casein, defatted milk powder, Lactalbumin concentrate (WPC), lactalbumin isolate (WPI), butter, buttermilk, the milk wet goods milk material.Such as cheese, natural cheese, yoghourt, fermented milk, milk surum (whey) fermented product, zieger etc. is included in the fermented dairy product used in the present invention.
And, after referring to liquid milk fermented as the cheese of fermented dairy product, add enzyme or add acid, remove the material after the milk surum from the curdled milk that forms thus, described liquid milk is modulated the one kind or two or more combination in milk, partially skimmed milk, defatted milk, recombined milk, reduction defatted milk, reduction partially skimmed milk, milk surum, casein, defatted milk powder, Lactalbumin concentrate (WPC), lactalbumin isolate (WPI), butter, buttermilk or the wet goods milk material of suckling.In the present invention, cheese can use the cheese of solid state and any of cheese of solid state not.And, in the present invention cheese can use (the ripening cheese) of ripening and do not have ripening (non-ripening cheese) any.
As the fermentation leaven for the manufacture of fermented dairy product, mainly can use the lactobacillus that belongs to lactobacillus (Lactobacillus) genus, streptococcus (Streptococcus) genus, Lactococcus (Lactococcus) genus, leukonid (Leuconostoc) genus, pediococci (Pediococcus) genus etc.But, be not limited to these, for example can use Streptococcus lactis (Lister) Lohnis 1909.554. (Streptococcus lactis), Streptococcus cremoris (Streptococcus cremoris), biacetyl streptococcus acidi lactici (Streptococcus diacetylactis), enterococcus faecalis (Enterococcus faecium), enterococcus faecalis (Enterococcus faecalis), bacillus acidophilus (Lactobacillus acidophilus), Lactobacillus brevis (Lactobacillus brevis), lactobacillus casei (Lactobacillus casei), lactobacillus helveticus (Lactobacillus helveticus), lactobacillus delbruockii subspecies bulgaricus (Lactobacillus delbrueckii subsp.Bulgaricus), Lactobacillus delbrueckii subsp. lactis (Lactobacillus delbrueckii subsp.lactis), Lactobacillus gasseri (Lactobacillus gasseri), Lactobacillus mucosae (Lactobacillus mucosae), Lactobacillus murinus (Lactobacillus murinus), Lactobacillus plantarum (Lactobacillus plantarum), oral cavity lactobacillus (Lactobacillus oris), Lactobacillus reuteri (Lactobacillus reuteri), lactobacillus rhamnosus (the lactobacillus such as Lactobacillus rhamnosus, bifidobacterium longum (Bifidobacterium longum), bifidobacterium (Bifidobacterium bifidum), the lactobacillus bifiduses such as bifidobacterium breve (Bifidobacterium breve).In addition, these bacterium and the bacterium that the bacterium (Propionibacterium) etc. that belongs to propionibacterium is generally used for the manufacturing of fermented dairy product can be share.
In the present invention, these leavens can use a kind or make up more than 2 kinds and to use.
Mineral absorption improving agent of the present invention so long as fermented dairy product just can prepare with any.Fermented dairy product is preferably non-ripening cheese (fresh cheese) or yoghourt.
The general autofrettage of non-ripening cheese below is described.With the standardization such as raw material milk, bactofugation, homogenize, after the heat treated, carry out curdled milk manufacturing (leaven inoculation, Chymosin interpolation etc.).And then, carry out milk surum and separate (heating, curd cutting, centrifugalize, membrance separation etc.), can obtain final curdled milk as non-ripening cheese.For example, with the defatted milk pasteurization, take with respect to defatted milk (100 quality %) as the amount inoculating lactic acid bacterium leavening agent of 0.5～5 quality % (such as the lactobacillus that belongs to Lactobacillus, belong to the lactobacillus of Streptococcus etc.), make its fermentation.Thereafter, with pH reach 4.6 and the curdled milk that forms with centrifugal separators such as cheese seperators (quark separator), sepg whey is with resulting curdled milk cooling.Thus, can access non-ripening cheese.
One example of the composition (mass unit) of the non-ripening cheese that obtains like this is, total solid composition 17～19%, protein 11～13%, fat below 1%, carbohydrate 2～8%, lactose are below 2%.
In addition, use Chymosin to solidify and the curdled milk that obtains also belongs to non-ripening cheese of the present invention.
Behind the defatted milk pasteurization, use the bacterium belong to Lactococcus also to can be used as non-ripening cheese of the present invention as the lactobacillus leaven fermented dairy product (cheese (quark) etc.) that forms that ferments.
And, also the mixed culture that belongs to lactis bacterium and the cremoris bacterium of Lactococcus and belong to the strain of Leuconostoc can be added in the defatted milk, after the cultivation, remove milk surum, make non-ripening cheese.
And, the curdled milk that will obtain by fermentation with cutter cuts after, the lower sepg whey of heating, resulting non-ripening cheese also can use in the present invention.
As the absorption approach of the mineral that absorbs, known cellular pathways (transcellular pathway) and the paracellular pathway (paracellular pathway) worn.For example in the situation of zinc, mainly absorb at duodenum and jejunum.Be under the condition of low concentration at the intraluminal zinc of small intestinal, the absorbing activity of wearing cellular pathways (transcellular pathway) increases.The intraluminal zinc of small intestinal is under the condition of high concentration, can say the help of paracellular pathway (paracellular pathway) large.And, pointed out ileum and colon also can absorb zinc (long Tian Changshi, Ami lead-biological meaning Righteousness, must Shall, そ て food To ぉ け Ru ying is with (zinc-biological meaning, essential and application in food), chemical と biological (chemistry is with biological), 46, pp.629-635 (2008); With Cousins RJ, the up-to-date Sakae Raising of the 35: Ami lead in Graduate Door Collar up-to-date feelings Reported in territory learns (zinc is in the up-to-date nutrition of the up-to-date information of specialized field) the 9th edition, translation chief editor: the Kimura repaiies one, the holt equating, build silks society, pp.443-455 (2007)).Mineral absorption improving agent of the present invention is not limited to above-mentioned various mechanism, has the effect that improves mineral absorption.
Mineral absorption improving agent of the present invention has the effect of the absorption that improves zinc.Therefore, can be used for preventing and/or treating that hypoevolutism and unusual, sexual dysfunction, anemia, immunodeficiency, dermatosis, diarrhoea, wound healing are slow, the generation of decubital ulcer and cure slow, inappetence and go down, the zinc deficiencys such as dysgeusia, glossodynia, impaired glucose tolerance.Mineral absorption improving agent of the present invention can also excise such gastric acid secretion minimizing person such as patient or People as the administration object take people, the stomach of taking gastric acid nertralizer (sodium bicarbonate, gel aluminum hydroxide and magnesium hydroxide compounding ingredient etc.) or gastric acid secretion depressant (proton pump inhibitor, H2 blocker etc.) etc. except being used for Healthy People.And then mineral absorption improving agent of the present invention also can use utilizing feeding tube and the people who accepts enteral nutrition.
Mineral absorption improving agent of the present invention is by making up fermented dairy product and oligosaccharide to bring into play the cooperative effect of these two kinds of materials, can promote with the amount (content in the solid constituent total amount) of the dosage that is lower than the indigestibility saccharide (oligosaccharide etc.) that the promotion zinc of report in the past absorbs the absorption of zinc.Therefore, follow the picked-up of a large amount of indigestibility saccharides and to produce the probability of the gastrointestinal symptoms such as diarrhoea low.And to block the probability of other mineral absorptions such as copper also low because absorbing excessive zinc.
The oligosaccharide and the fermented dairy product that contain as effective ingredient in the mineral absorption improving agent of the present invention are the materials that has long-term diet experience concerning the mankind, and be no problem on the sense of taste, safe, so can absorb for a long time.
Mineral absorption improving agent of the present invention prepares as the mixture of oligosaccharide, fermented dairy product and other any compositions usually, but also can be prepared into other forms, for example separately is prepared into the preparation that contains oligosaccharide and the preparation that contains fermented dairy product.When separately being prepared into the preparation that contains oligosaccharide and containing the preparation of fermented dairy product, preferably take the photograph taker and absorb simultaneously the preparation that contains oligosaccharide and the preparation that contains fermented dairy product.
Mineral absorption improving agent of the present invention can utilize with arbitrary form of food compositions (diet product) and pharmaceutical composition (pharmaceuticals).For example, by as the direct administration of pharmaceutical composition, or directly absorb as food compositions such as the special purposes food such as specific food for health care or trophic function food, can expect to improve the absorption of mineral.And mineral absorption improving agent of the present invention also can be with arbitrary form utilization of liquid state, pasty state, gel, solid-state (such as powder, tablet etc.).
In the present invention, as food compositions, can enumerate such as milk, cold drink, fermented milk, yoghourt, cheese, bread, cookies, cracker, pizza, formula milk, liquid food, patient with food, nutraceutical, frozen food, food compositions, processed food, other delicatessen food etc.
When using mineral absorption improving agent of the present invention with the form of the pharmaceutical composition of acidity or food compositions, its pH is preferably pH2.0～pH6.0, pH3.0～pH5.0 more preferably.
Mineral absorption improving agent of the present invention can contain water, protein, saccharic, lipid, vitamins, minerals, organic acid, organic base, fruit juice, flavoring agent class etc.
As protein, can enumerate the various newborn derived components such as of animal or plant nature protein such as whole milk powder, defatted milk powder, partially skimmed milk powder, casein, whey powder, whey protein, whey protein concentrate, whey protein sepd, alpha-casein, beta-casein, κ-casein, beta lactoglobulin, lactoferrin, soybean protein, egg protein, meat protein or their analyte, butter, whey mineral, butter, milk surum, non-protein nitrogen, sialic acid, phospholipid, lactose etc.
Protein also can contain peptide or the aminoacid such as phosphopeptide caseinate, arginine, lysine.
As saccharic, can enumerate such as saccharide, producing starch (dextrin (maltodextrin, difficult digestion dextrin etc.) and soluble starch, Britain starch (British starch), Oxytarch, starch ester, starch ether etc.), dietary fiber etc.
As lipid, can enumerate such as Adeps Sus domestica, fish oil etc., their distillate oil, hydrogenated oil and fat, ester exchange wet goods animal raw fat; Petiolus Trachycarpi oil, safflower oil, Semen Maydis oil, Oleum Brassicae campestris, Oleum Cocois, their distillate oil, hydrogenated oil and fat, ester exchange wet goods vegetative grease etc.
As vitamins, can enumerate such as vitamin A, carotenoid, vitamin B complex, vitamin C, vitamin D family, vitamin E, vitamin K family, Citrin, CoenzymeQ10, nicotinic acid (niacin), nicotinic acid, pantothenic acid, biotin, inositol, choline, folic acid etc.
As minerals, can enumerate such as calcium, phosphorus, potassium, chlorine, magnesium, sodium, copper, ferrum, manganese, zinc, selenium, chromium, molybdenum etc.
Wherein, preferred zinc, this is because even simultaneously picked-up other food of containing zinc only absorb mineral absorption improving agent of the present invention, just can absorb for the enough zinc of organism.
As organic acid, can enumerate such as malic acid, citric acid, lactic acid, tartaric acid etc.
Mineral absorption improving agent of the present invention can and derive from the goods of natural goods any for composite.
When mineral absorption improving agent of the present invention is used as pharmaceutical composition, can be with various form administrations.As its form, can enumerate such as the oral administration based on tablet, capsule, granule, powder, syrup etc.Also can be processed into the preparations such as injection, liquid preparation, by other administration form administrations such as feeding tube feeding, enteral nutrition.For these various preparations, can use common available known adjuvant in the pharmaceutical preparations technology field and preparation in host according to conventional method, described adjuvant is excipient, binding agent, disintegrating agent, lubricant, flavoring agent, cosolvent, suspending agent, coating materials, solvent, isotonic agent etc.And, also can contain an amount of calcium.And then, also can add an amount of vitamin, mineral, organic acid, saccharide, aminoacid, peptide class etc.
In the solid constituent total amount of mineral absorption improving agent of the present invention (100 quality %) concentration of contained oligosaccharide be preferably 1.0～7.0 quality %, more preferably 1.5～6.5 quality %, more preferably 2.5～6.0 quality %, be particularly preferably 4.0～6.0 quality %.
In the solid constituent total amount of mineral absorption improving agent of the present invention (100 quality %) concentration of contained fermented dairy product be preferably 5.0～98 quality %, more preferably 10～98 quality %, more preferably 15～98 quality %, be particularly preferably 18～96 quality %.
Need to prove, in this description, only otherwise special declaration, the quality of solid constituent just means dried quality (quality that comprises liquid oils and fats) under 20 ℃ the dry atmosphere in exsiccator, and does not mean that the quality of the aqueous solid composition that powder feed is such.
Be preferably 0.05mg～2g, more preferably 0.5mg～1g, 5mg～0.2g more preferably as per 1 day every 1kg body weight of administration (picked-up) amount of the oligosaccharide of the effective ingredient of mineral absorption improving agent of the present invention in solid component content.
Be preferably 1mg～10g, more preferably 10mg～5g, 50mg～2.5g more preferably as per 1 day every 1kg body weight of administration (picked-up) amount of the fermented dairy product of the effective ingredient of mineral absorption improving agent of the present invention in solid component content.
As the oligosaccharide of the effective ingredient of mineral absorption improving agent of the present invention to dosage every day of people in solid component content be preferably 0.01g～15g, more preferably 0.1g～10g, be particularly preferably 1g～8g.
As the fermented dairy product of the effective ingredient of mineral absorption improving agent of the present invention to dosage every day of people in solid component content be preferably 0.1g～500g, more preferably 1g～250g, be particularly preferably 2.5g～150g.
To the people of the treatment that needs mineral absorption improving agent of the present invention, aptly in ante cibum, after meal, between meal and/or before sleeping once or the gradation administration.Dosage is independently determined according to the patient's of administration age, body weight and administration purpose.Dosage not necessarily is limited in the above-mentioned numerical range.
In the present invention, the mass ratio of fermented dairy product/oligosaccharide (solid constituent scaled value) is preferably 1.0～49.0, more preferably 1.0～30.0, more preferably 1.0～9.0, is particularly preferably 3.0～8.0.
Contain in the situation of zinc at mineral absorption improving agent of the present invention, in the solid constituent total amount of mineral absorption improving agent (100 quality %) contained zinc concentration when considering the intake of the desirable zinc of people, be preferably 0.01～1.0 quality %, more preferably 0.01～0.8 quality %, be particularly preferably 0.1～0.6 quality %.
Need to prove that the content of whole prior art document records of quoting in this description is included in this description by reference.
Embodiment
Below, the present invention will be described to enumerate embodiment, but the invention is not restricted to these embodiment.
[embodiment 1] (effect that gives zinc is absorbed generation of fermented dairy product and oligosaccharide)
Present embodiment checked fermented dairy product and oligomeric galactose (below be also referred to as GOS) give zinc is absorbed the impact that produces.
(preparation of fermented dairy product)
Make non-ripening cheese according to conventional method.Specifically, after the defatted milk powder sterilization, ferment with the lactobacillus that belongs to Lactobacillus and the lactobacillus that belongs to Streptococcus, and then add Chymosin.And then, with formed curd cutting, carry out centrifuging treatment, the precipitate (non-ripening cheese) that obtains is supplied in test as fermented dairy product.
(animal experiment method)
56 of the male SD rats in 3 ages in week are divided into following 5 groups (n=8) so that average weight homogeneous (about 47g).
(a) health+casein feedstuff is organized [matched group]
(b) gastric acid minimizing+casein feedstuff is organized [casein group]
(c) gastric acid minimizing+5.0 quality %GOS cooperate the casein feedstuff to organize [casein G group]
(d) gastric acid minimizing+fermented dairy product feedstuff is organized [fermented dairy product group]
(e) gastric acid minimizing+5.0 quality %GOS cooperate the fermented dairy product feedstuff to organize [fermented dairy product G group]
Each group to (a)～(e) gives each test feed 9 days (day1～9), freely absorbs.Wherein, the casein feedstuff is common AlN-93G to be carried out part change and the feedstuff of preparation.The fermented dairy product feedstuff is to cooperate fermented dairy product to replace casein so that the protein content feedstuff (table 1) identical with the casein feedstuff.And 5.0 quality %GOS mixed feeds are to cooperate 5.0 quality %GOS and the feedstuff (table 1) that obtains in feedstuff 100 quality %.Need to prove, adjust the content identical (table 1) in whole feedstuffs of calcium, phosphorus, magnesium, ferrum, zinc, copper.
For gastric acid minimizing group (above-mentioned (b)～(e)), from the 5th day on-test to off-test (day5～9) 7:00 every day, twice subcutaneous administration proton pump inhibitor of 19:00 (PPI, gastric acid secretion inhibitor) Omepral (below be also referred to as OM, omeprazole sodium injection, AstraZeneca Co., Ltd. make), dosage is 20mg/kg (body weight) (OM concentration: 4mg/ml, administration volume: 5ml/kg (body weight)), makes the gastric acid secretion continuous decrease.To health group (above-mentioned (a)), with the normal saline 5ml/kg (body weight) of the same process subcutaneous administration of the PPI administration of gastric acid minimizing group as the solvent of OM.From the second day (day6) of beginning PPI administration, use metabolic cage to carry out 4 days (day6～9) energy balance tests, by each individual full excrement that reclaims whole rats.The mensuration that the excrement that gathers is used for the excretion of zinc.And, from the second day (day6) of beginning PPI administration, to the feed intake of each body measurement 4 days (day6～9).Calculate the zinc intake by 4 days feed intakes, calculate the apparent absorption rate (quality %) of each individual zinc with following formula.
The apparent absorption rate (%) of zinc=(zinc excretion in zinc intake-excrement) * 100/ (zinc intake)
Need to prove, at whole duration of test, make rat freely absorb ion exchange water.And the average feed intake of every day is about 114g/kg (body weight), and the average weight at initial stage on-test (day2) is 57g, and the average weight of (day9) is 110g during off-test.Do not observe the difference that has feed intake, body weight between each group.
[table 1]
Table 1 has provided the composition of feedstuff used among the embodiment 1.In the table 1, mineral mixture uses to be removed calcium source, phosphorus source, the magnesium source of AlN-93G mineral mixture and replaces with mineral mixture after the sucrose.The vitamin compound uses AlN-93 vitamin compound.Cup-oligo (trade name, NISSIN CUP society make, Determination of galactooligosacchariin: 73 quality %, " Cup-oligo " are registered trade mark) is to contain oligomeric galactose as the goods of main constituent, contains with several compositions headed by 4 '-galactosyl lactose (Gal-(Gal) n-Glc, Gal-(Gal) n-Gal (n=1～3, β bonding)).The proportioning of mineral mixture used among the embodiment 1 and vitamin compound is listed in table 2 and table 3.
[table 2]
Mineral mixture
The use level of every 1000g
[table 3]
The vitamin compound
The use level of every 1000g
Need to prove, AlN-93G mineral mixture and AlN-93 vitamin compound are the standard refined feedstuffs that the nutrient research of the Mouse and rat delivered in 1993 by U.S.'s National Nutrition Research Institute (AlN) is used, and refer to be engaged in vitamin compound and mineral mixture for the AlN-93G of growth stage, trimester of pregnancy, age of sucking.
(result)
(a) the apparent absorption rate of the zinc between matched group and (b) casein group is identical.Thought that by this result the gastric acid secretion due to the PPI administration reduces the almost not impact (Fig. 1) of apparent zinc absorbance.And, compare with other groups, (e) the apparent zinc absorbance of fermented dairy product G group shows obviously (p＜0.05, Tukey-Kramer multiple check) high value, relative therewith, (c) casein G group is compared with (d) fermented dairy product group with (b) casein group, does not confirm notable difference.By this result as can be known, even contain separately the feedstuff of GOS, do not have the effect of zinc absorption enhancement yet, but by itself and fermented dairy product are given simultaneously, promoted to concertedness the absorption (Fig. 1) of zinc.
Need to prove that among Fig. 1, literal a, the b of the top of bar diagram represents that notable difference is arranged between different literal (p＜0.05, Tukey-Kramer multiple check).And " w/w% " among Fig. 1 refers to quality %.
Industrial applicibility
Mineral absorption improving agent of the present invention can be effective to prevent and/or treat various mineral deficiencies.
Claims (8)
1. mineral absorption improving agent, it contains oligomeric galactose and fermented dairy product as effective ingredient, be used for improving gastric acid secretion minimizing person's mineral absorption, wherein, described fermented dairy product is to utilize the lactobacillus that belongs to Lactobacillus and the lactobacillus that belongs to Streptococcus that the milk fermentation is obtained, the mineral of the object that improves as the absorption of described mineral absorption improving agent is zinc, the content of described oligomeric galactose in the solid constituent total amount of described mineral absorption improving agent is 1.0～7.0 quality %, and the mass ratio of described fermented dairy product/described oligomeric galactose is 1.0～49.0 by the value that solid constituent converts.
2. mineral absorption improving agent as claimed in claim 1, wherein, the mass ratio of described fermented dairy product/described oligosaccharide is 1.0～30.0 by the value that solid constituent converts.
3. mineral absorption improving agent as claimed in claim 2, wherein, the mass ratio of described fermented dairy product/described oligosaccharide is 1.0～9.0 by the value that solid constituent converts.
4. mineral absorption improving agent as claimed in claim 3, wherein, the mass ratio of described fermented dairy product/described oligosaccharide is 3.0～8.0 by the value that solid constituent converts.
5. such as each described mineral absorption improving agent of claim 1～4, wherein, described fermented dairy product is non-ripening cheese.
6. such as each described mineral absorption improving agent of claim 1～5, wherein, this mineral absorption improving agent further contains zinc.
7. such as each described mineral absorption improving agent of claim 1～6, it is food compositions.
8. such as each described mineral absorption improving agent of claim 1～6, it is pharmaceutical composition.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2008-303517 | 2008-11-28 | ||
| JP2008303517 | 2008-11-28 | ||
| PCT/JP2009/069930 WO2010061877A1 (en) | 2008-11-28 | 2009-11-26 | Mineral absorption improver, and method for improving absorption of minerals |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102227223A CN102227223A (en) | 2011-10-26 |
| CN102227223B true CN102227223B (en) | 2013-03-20 |
Family
ID=42225748
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009801476120A Expired - Fee Related CN102227223B (en) | 2008-11-28 | 2009-11-26 | Mineral absorption improver, and method for improving absorption of minerals |
Country Status (4)
| Country | Link |
|---|---|
| JP (1) | JP5971893B2 (en) |
| CN (1) | CN102227223B (en) |
| HK (1) | HK1158060A1 (en) |
| WO (1) | WO2010061877A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6088821B2 (en) * | 2010-08-19 | 2017-03-01 | 株式会社明治 | Survivability improver for lactic acid bacteria and / or bifidobacteria |
| JP2012192339A (en) * | 2011-03-16 | 2012-10-11 | Denso Corp | Method and apparatus for treating wastewater containing organic matter |
| WO2014148886A1 (en) * | 2013-03-22 | 2014-09-25 | N.V. Nutricia | Fermented nutrition high in lactose with increased iron bioavailability |
| WO2014148887A1 (en) * | 2013-03-22 | 2014-09-25 | N.V. Nutricia | Fermented nutrition with non-digestible oligosaccharides with increased iron bioavailability |
| CN107105688B (en) * | 2015-01-20 | 2021-03-19 | 株式会社明治 | Composition for inhibiting phosphorus absorption |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1269724A (en) * | 1997-07-05 | 2000-10-11 | 雀巢制品公司 | Absorption of minerals by intestinal cells |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5871842A (en) * | 1981-10-21 | 1983-04-28 | Meiji Milk Prod Co Ltd | Preparation of unaged soft cheese capable of being preserved for a long period |
| JPH09194384A (en) * | 1996-01-19 | 1997-07-29 | Snow Brand Milk Prod Co Ltd | Mineral absorption accelerating agent |
-
2009
- 2009-11-26 WO PCT/JP2009/069930 patent/WO2010061877A1/en active Application Filing
- 2009-11-26 JP JP2010540500A patent/JP5971893B2/en active Active
- 2009-11-26 CN CN2009801476120A patent/CN102227223B/en not_active Expired - Fee Related
-
2011
- 2011-11-16 HK HK11112351.5A patent/HK1158060A1/en not_active IP Right Cessation
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1269724A (en) * | 1997-07-05 | 2000-10-11 | 雀巢制品公司 | Absorption of minerals by intestinal cells |
Non-Patent Citations (1)
| Title |
|---|
| JP特开平9-194384A 1997.07.29 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102227223A (en) | 2011-10-26 |
| JPWO2010061877A1 (en) | 2012-04-26 |
| JP5971893B2 (en) | 2016-08-17 |
| HK1158060A1 (en) | 2012-07-13 |
| WO2010061877A1 (en) | 2010-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4008974B2 (en) | Bifidobacterium growth promoting composition and use thereof | |
| CN103653170B (en) | Stachyose probiotics solid beverage | |
| CN103957720B (en) | Improving intestinal flora alimentation composition | |
| US20190069586A1 (en) | Food Compositions for Weaning | |
| CN103564044B (en) | A kind of Yoghourt containing marine alga and preparation method thereof | |
| CN104206539A (en) | Probiotic-containing infant milk powder | |
| CN108244252A (en) | Probiotics multielement protein powder and preparation method thereof | |
| CN105792673A (en) | Use of nutritional compositions having a low protein amount | |
| EP1374878A1 (en) | Method and composition for preventing or alleviating symptoms of malabsorption from the gastrointestinal tract | |
| CN102227223B (en) | Mineral absorption improver, and method for improving absorption of minerals | |
| JP2014196339A (en) | Composition for prevention or treatment of anemia | |
| CN102665738B (en) | Prophylactic composition for influenza infection | |
| CN102088981B (en) | Sialic acid to support salivation | |
| CN101199299A (en) | Lactobacillus milk beverage containing conjugated linoleic acid and preparation method thereof | |
| JP6773562B2 (en) | Sphingolipid absorption promoter | |
| JP2019513390A (en) | Bifidobacterium for reducing food, energy and / or fat intake | |
| CN108289919A (en) | Anti-allergic agent towards baby | |
| JP2009044976A (en) | Animal body type-improving feeding system | |
| CN111201026B (en) | Fermented milk and polysaccharides with cancer cachexia inhibiting effect | |
| CN104430880A (en) | Production process of passion fruit and water-chestnut flavored probiotic yoghourt | |
| CN104430877A (en) | Production process of passion fruit flavored probiotic yoghourt | |
| CN104430878A (en) | Production technology of cranberry flavor probiotic yogurt | |
| TWI692360B (en) | Composition for inhibiting phosphorus absorption | |
| CN103749675A (en) | Conjugated linoleic acid-containing lactobacillus milk beverage and production method thereof | |
| Singh et al. | Development of probiotics and prebiotics product as weaning food for infants |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1158060 Country of ref document: HK |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1158060 Country of ref document: HK |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130320 Termination date: 20191126 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |